|
Market Closed -
Nasdaq
23:00:00 18/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 5.130 USD | +0.39% |
|
+1.79% | -41.84% |
| 08-24 | Vanda Pharmaceuticals' Skin Disease Drug Gets EU Orphan Drug Designation | MT |
| 08-10 | B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating | MT |
| Market Cap | 309M 269M 254M 231M 433M 29.65B 435M 3.05B 1.18B 15.07B 1.16B 1.13B 48.5B | P/E 2026 * |
-1.69x | P/E 2027 * | -4.96x |
|---|---|---|---|---|---|
| Enterprise Value | 309M 269M 254M 231M 433M 29.65B 435M 3.05B 1.18B 15.07B 1.16B 1.13B 48.5B | EV / Sales 2026 * |
1.24x | EV / Sales 2027 * | 0.92x |
| Free-Float |
90.83% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VNDA | Delayed | |
CBOE
| VNDA | Real-time | |
|
London S.E.
| 0LKB | Delayed | |
|
Deutsche Boerse AG
| VM4 | Delayed | |
|
Börse Stuttgart
| VM4 | Delayed | |
|
Tradegate
| VM4 | Real-time | |
|
Berne S.E.
| VM4 | End-of-day quote | |
|
Boerse Muenchen
| VM4 | Real-time |
Last Transcript: Vanda Pharmaceuticals Inc.
| 1 day | +0.39% | ||
| 1 week | +1.79% | ||
| Current month | -5.00% | ||
| 1 month | -2.47% | ||
| 3 months | -13.93% | ||
| 6 months | -40.35% | ||
| Current year | -41.84% |
| 1 week | 4.94 |  | 5.19 |
| 1 month | 4.94 | | 5.64 |
| Current year | 4.45 | | 9.94 |
| 1 year | 4.27 | | 9.94 |
| 3 years | 3.3 | | 9.94 |
| 5 years | 3.3 | | 21.44 |
| 10 years | 3.3 | | 33.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 01/05/2003 | |
Kevin Moran
DFI | Director of Finance/CFO | 42 | 15/03/2020 |
Scott Howell
HRO | Human Resources Officer | 51 | 01/08/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 66 | 01/06/2021 | |
Richard Dugan
BRD | Director/Board Member | 84 | 01/12/2005 |
Phaedra Chrousos
BRD | Director/Board Member | 46 | 24/04/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/4/26 A | Free | Director | 41,600 | 0.0692% | ||
| 6/4/26 A | Free | Director | 41,600 | 0.0692% | ||
| 6/4/26 A | Free | Director | 41,600 | 0.0692% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.39% | +1.79% | +16.86% | +9.15% | 309M | |
| -0.31% | +3.56% | +46.40% | +100.50% | 70.89B | |
| +0.39% | +1.82% | +38.93% | +77.73% | 62.32B | |
| -3.21% | -5.72% | -17.12% | +350.96% | 27.07B | |
| -2.64% | -0.35% | -2.13% | -15.04% | 24.78B | |
| +0.71% | +8.50% | +27.76% | -15.29% | 20.59B | |
| -1.26% | -10.61% | +170.72% | +290.48% | 15.52B | |
| -0.22% | +1.62% | +44.31% | +167.58% | 14.49B | |
| +0.73% | +5.00% | -1.33% | +854.55% | 14.14B | |
| -0.54% | -0.30% | +27.33% | +202.19% | 12.35B | |
| Average | -0.60% | +1.65% | +35.17% | +202.28% | 26.25B | |
| Weighted average by Cap. | -0.59% | +1.39% | +35.77% | +161.16% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 249M 217M 205M 186M 348M 23.86B 350M 2.45B 946M 12.13B 934M 913M 39.03B | 337M 294M 277M 252M 472M 32.33B 474M 3.32B 1.28B 16.44B 1.27B 1.24B 52.89B |
| Net income | -181M -158M -149M -136M -254M -17.4B -255M -1.79B -690M -8.85B -681M -666M -28.47B | -75.35M -65.71M -62.04M -56.34M -106M -7.23B -106M -743M -287M -3.68B -283M -277M -11.83B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/09/26 | $5.130 | +0.39% | 1,657,785 |
| 17/09/26 | $5.110 | +2.20% | 646,828 |
| 16/09/26 | $5.000 | +0.20% | 441,253 |
| 15/09/26 | $4.990 | -3.11% | 758,873 |
| 14/09/26 | $5.150 | +1.18% | 817,814 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VNDA Stock
Select your edition
All financial news and data tailored to specific country editions
